ProPhase Labs, Inc. to Post Q1 2024 Earnings of ($0.15) Per Share, Diamond Equity Forecasts (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH) – Diamond Equity lowered their Q1 2024 earnings estimates for shares of ProPhase Labs in a report issued on Monday, April 22nd. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($0.15) per share for the quarter, down from their prior forecast of ($0.11). The consensus estimate for ProPhase Labs’ current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs’ Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at $0.04 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at ($0.10) EPS and FY2025 earnings at $0.48 EPS.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Stock Down 2.2 %

ProPhase Labs stock opened at $4.95 on Thursday. The company’s 50 day simple moving average is $5.54 and its 200 day simple moving average is $5.00. ProPhase Labs has a fifty-two week low of $4.05 and a fifty-two week high of $9.94. The firm has a market capitalization of $89.35 million, a price-to-earnings ratio of -5.05 and a beta of -0.29. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.28 and a quick ratio of 2.10.

ProPhase Labs (NASDAQ:PRPH) last issued its earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. The business had revenue of $3.50 million during the quarter, compared to the consensus estimate of $10.71 million. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%.

Hedge Funds Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its position in ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company’s stock worth $68,000 after purchasing an additional 5,026 shares during the period. SVB Wealth LLC bought a new stake in shares of ProPhase Labs in the third quarter valued at about $208,000. Finally, HighTower Advisors LLC bought a new stake in shares of ProPhase Labs in the third quarter valued at about $756,000. 9.45% of the stock is owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.